CASEY BUTTS: Open Payments
NPI 1154725075 · OKLAHOMA CITY, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$380 in 21 payments from 11 companies in 2025. Trend: 2023 $578 · 2024 $390 · 2025 $380
Food & beverage: $380
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 8 | $170 |
| Sumitomo Pharma America, Inc. | 3 | $52 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| IBSA Pharma Inc. | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $15 |
| Acella Pharmaceuticals, LLC | 1 | $15 |
| PFIZER INC. | 1 | $14 |
Products named: Veozah, MYFEMBREE, UNITHROID, Tirosint, ZEPBOUND, Lynkuet, ONZETRA XSAIL, XIFAXAN.
Industry payments across OK — which companies pay providers there.
